FB102

DRUG3 trials

Sponsors

Forte Biosciences, Inc.

Conditions

Alopecia AreataCeliac DiseaseVitiligo

Phase 1

A Study to Evaluate the Safety and Efficacy of FB102 in Patients With Non-segmental Vitiligo

RecruitingNCT06905873

Forte Biosciences, Inc.Vitiligo

Start: 2025-03-25End: 2026-12-31Target: 64Updated: 2025-11-20

A Study to Evaluate the Safety and Efficacy of FB102 in Patients With Severe to Very Severe Alopecia Areata.

RecruitingNCT07205159

Forte Biosciences, Inc.Alopecia Areata

Start: 2025-10-23End: 2027-03-10Target: 32Updated: 2025-11-20

Phase 2

Randomized, Double Blind, Placebo-controlled Phase 2 Study in Adults With Celiac Disease

RecruitingNCT06982963

Forte Biosciences, Inc.Celiac Disease

Start: 2025-08-04End: 2027-02-28Target: 100Updated: 2025-11-18